CAJ | 학술논문

目的：评价奥沙利铂联合雷替曲塞治疗结直肠癌经一线治疗失败后出现肝转移的近期疗效和毒副反应。方法选取39例晚期结直肠癌患者经FOLFOX、 FOLFIRI或XELOX方案化疗后复发出现肝转移患者,奥沙利铂130 mg/m2,第1天静滴,雷替曲塞3 mg/ m2,第2天静滴,避凉保温护理3 d,21 d为1周期,每两个周期评估疗效,直至疾病进展或出现不能耐受毒副反应。结果经奥沙利铂联合雷替曲塞治疗后有效率( RR)为28.2%,肿瘤控制率( DCR)为76.9%。毒副反应主要是I~II度的恶心呕吐(56.4%)、转氨酶升高(48.7%)和周围神经毒性(46.2%)。结论结直肠癌患者经FOLFOX、 FOLFIRI或XELOX方案化疗后复发出现肝转移,应用奥沙利铂联合雷替曲塞治疗仍然有效,毒副反应可耐受。
목적：평개오사리박연합뢰체곡새치료결직장암경일선치료실패후출현간전이적근기료효화독부반응。방법선취39례만기결직장암환자경FOLFOX、 FOLFIRI혹XELOX방안화료후복발출현간전이환자,오사리박130 mg/m2,제1천정적,뢰체곡새3 mg/ m2,제2천정적,피량보온호리3 d,21 d위1주기,매량개주기평고료효,직지질병진전혹출현불능내수독부반응。결과경오사리박연합뢰체곡새치료후유효솔( RR)위28.2%,종류공제솔( DCR)위76.9%。독부반응주요시I~II도적악심구토(56.4%)、전안매승고(48.7%)화주위신경독성(46.2%)。결론결직장암환자경FOLFOX、 FOLFIRI혹XELOX방안화료후복발출현간전이,응용오사리박연합뢰체곡새치료잉연유효,독부반응가내수。
Objective To investigate the clinical efficacy and safety of raltitrexed combined with oxaliplatin in the treatment of colorectal cancer liver metastases after failure in first-line treatment. Methods A total of 39 colorectal cancer patients with liver me-tastases were treated by raltitrexed and oxaliplatin after they failed in FOLFOX, 1FOLFIRI or XELOX. They were given oxaliplatin, 130 mg/m2 ivgtt, d1; raltitrexed, 3mg/ m2 ivgtt, d2 and cold insulation care, d3, with 21 days as a cycle, until there was evi-dence of disease progression or intolerance in the treatment. Results After the combined treatment of raltitrexed and oxaliplatin, RR reached 28. 2%, and DCR was 76. 9%. The main side effects were nausea and vomiting, elevated transaminase and peripheral neuro-toxicity with incidence rates of 56. 4%, 48. 7% and 46. 2% respectively. Conclusion The treatment method, raltitrexed combined with oxaliplatin, after the failure in FOLFOX, FOLFIRI or XELOX proves to effective for colorectal cancer patients with liver metasta-ses, with tolerance to toxicity.